Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCADE: HC-1119 vs enzalutamide in metastatic castration-resistant prostate cancer
2019-001144-22Phase 3Terminated
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deutenzalutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Hinova Pharmaceuticals Inc. Primary endpoint: Overall response rate by RECIST 1.1 until 24 weeks. Started Aug 2019; status: terminated.
02
Drugs
deutenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2019-001144-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001144-22.